熱門資訊> 正文
Citius Pharmaceuticals GAAP每股收益为-3.38美元
2025-12-24 05:35
- Citius Pharmaceuticals press release (CTXR): FY GAAP EPS of -$3.38.
- Cash and cash equivalents of $4.3 million as of September 30, 2025;
- Citius Pharma did not report revenues for the year;
- R&D expenses were $9.2 million for the full year ended September 30, 2025, compared to $11.9 million for the full year ended September 30, 2024;
- G&A expenses were $18.5 million for the full year ended September 30, 2025, compared to $18.2 million for the full year ended September 30, 2024;
- Stock-based compensation expense was $10.8 million for the full year ended September 30, 2025, compared to $11.8 million for the full year ended September 30, 2024; and,
More on Citius Pharmaceuticals
- Citius Pharmaceuticals GAAP EPS of -$3.38 misses by $0.25
- Citius Oncology announces $18 million registered direct offering
- Seeking Alpha’s Quant Rating on Citius Pharmaceuticals
- Historical earnings data for Citius Pharmaceuticals
- Financial information for Citius Pharmaceuticals
推薦文章
華盛早報 | 黃金、白銀狂飆！特朗普「威脅」引地緣政治風險升溫；商業航天爆發！中國新增20萬顆衞星申請
港股周報 | 超配中國！高盛稱中國股市26年大漲15%至20%；阿里稱堅定加大淘寶閃購投入
2026年展望 | 智能駕駛元年或開啟！特斯拉Robotaxi引爆賽道，港美股哪些標的值得佈局？
美股機會日報 | 重磅大考！「非農+關税裁決」今夜同台亮相；Meta宣佈將投資核電廠，OKLO等核電股盤前飆升！
一周財經日曆 | 美國12月CPI攜手「恐怖數據」來襲；華爾街大行啟動Q4財報季，臺積電財報或炸場！4只港股新股即將上市
一周IPO | 吃大肉！本周六只新股上市大漲，MINIMAX暴漲109%；BBSB INTL孖展倍數超8900倍，位列史上第三
財報前瞻 | 臺積電Q4營收料衝破萬億新臺幣！大摩喊話績前買入，2026年股價還能「繼續飛」嗎？
MiniMax上市首日漲超60%，阿里、米哈遊等投資方「躺贏」
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
